ERAS

Conviction 66HealthcareScan · Tue, Sep 8, 2026

ERAS$16.30+0.65%

ResistanceSupportVol 14

Vol MA14 3.91M

Jun 9Jun 26Jul 16Aug 3Aug 20Sep 8

Erasca, Inc.PHARMACEUTICAL PREPARATIONSwww.erasca.com ↗

Price16.30

Change+0.65%

Gap-0.99%

Rel volume1.22×

Avg volume3.55M

Avg $ vol62.95M

SMA 2017.70

SMA 5018.30

SMA 20012.91

Price vs 50-10.97%

Price vs 200+26.23%

MA stackmixed

50/200 cross—

Supertrenddown · 19.46

RSI (14)39

MACD hist-0.25

MACD crossbear · 5d

Stoch %K / %D11 / 10

ADX (14)15

+DI / −DI17 / 26

RSI divergence—

MACD divergence—

ATR %+6.85%

ADR %6.19%

52w high22.47

52w low1.55

From 52w high-27.48%

Above 52w low+951.29%

New 52w highNo

SqueezeOff

Bollinger width20.89%

%B0.12

Donchian pos11.34%

Donchian high20.40

Donchian low15.77

AVWAP (52w high)15.07

vs AVWAP high+8.13%

AVWAP (52w low)12.25

vs AVWAP low+33.04%

OBV trendFlat

Chaikin MF (20)-0.12

Today vs 20d1.22×

Avg vol (14d)3.91M

Avg vol (20d)3.55M

Avg $ vol (20d)62.95M

Market cap5.7B

RS 3m (vs SPY)+30.83%

RS 6m (vs SPY)-9.89%

RS line new highNo

Trend template6/8

Technical rank47.9

1 week-8.86%

1 month-11.49%

3 months+26.61%

6 months+3.39%

1 year+912.11%

YTD+353.90%

P/E-45.76

P/B15.75

P/S—

P/FCF-59.63

EPS-0.4400

Div yield—

ROE-34.42%

ROA-28.63%

Debt/Eq—

Current8.29

EV/EBITDA-41.05

Gross margin—

Net margin—

Rev growth—

EPS growth22.95%

Price target24.13

Target upside48.08%

Analyst ratingBuy

Institutional84.87%

Ent. value5.66B

Revenue—

Net income-44.08M

Gross profit—

Free cash flow-95.58M

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out310.98M

Employees103

ListedFri, Jul 16, 2021

Free float219.65M

Float %77.4%

Short interest30.85M

Days to cover10.0d

Short volume46.8%

Squeeze score61 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$0.14 vs −$0.12

Last surprise-16.7% miss

Setup gradeB

Conviction66 / 100

Pattern quality—

Tech rank47.9 / 100

Group rank96 / 100 · Leading

Status laneNo active setup

Setup direction—

Pattern family

Resistance20.18

Support16.98

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in ERAS

All disclosures →

No recent disclosed trades by Congress in ERAS. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in ERAS · 7 buys

Insider	Side	Shares	Value	Traded	Filed
Fuchs Charles S. President, R&D · Stock option (right to buy) · 2026-08-10	Grant	1.3M	—	2026-08-10	2026-08-12
Hambleton Julie Director · Stock option (right to buy) · 2026-06-26	Grant	29.89K	—	2026-06-26	2026-06-29
Bristol James Arthur Director · Stock option (right to buy) · 2026-06-26	Grant	29.89K	—	2026-06-26	2026-06-29
LIU JEAN I Director · Stock option (right to buy) · 2026-06-26	Grant	29.89K	—	2026-06-26	2026-06-29
Casdin Alexander W. Director · Stock option (right to buy) · 2026-06-26	Grant	29.89K	—	2026-06-26	2026-06-29
Multani Pratik S Director · Stock option (right to buy) · 2026-06-26	Grant	29.89K	—	2026-06-26	2026-06-29
Start Valerie Denise Harding Director · Stock option (right to buy) · 2026-06-26	Grant	29.89K	—	2026-06-26	2026-06-29

SEC filings

EDGAR filings in ERAS · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.

ERAS

Recent news

Get daily signals & real-time alerts.